Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug
Phase 4
Completed
- Conditions
- Epilepsy, Tonic-Clonic
- Registration Number
- NCT00043901
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
The purpose of this study is to evaluate the effectiveness and safety of an investigational new drug for supplemental therapy in subjects with primary generalized tonic-clonic (PGTC) seizures.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 141
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method % change from Baseline in average monthly PGTC seizure frequency
- Secondary Outcome Measures
Name Time Method Proportion of subjects with >/= 25%, 50%, 75% or 100% reduction in PGTC seizures %change from Baseline in average monthly seizure frequency.
Trial Locations
- Locations (1)
GSK Investigational Site
🇵🇪San Isidro, Lima, Peru